Research paper

The Science Behind NMN—A Stable, Reliable NAD+ Activator and Anti-Aging Molecule

Christopher Shade

Integrative Medicine (Encinitas) 2020 Volume 19, Issue 1, pages 12–14

Tier 4 · Early mechanistic or hypothesis-generatingNAD+ metabolism

Source identifiers

DOI __
PubMed PMID 32549859
Funding Not disclosed in the article.
Declared competing interests Not disclosed in the article. However, the author is founder and CEO of Quicksilver Scientific, a nutraceutical company that markets a liposomal NMN supplement. The article's closing section advocates for liposomal delivery of NMN.

Study snapshot

Design
Narrative perspective / opinion article. Not systematic review, not primary research.
Population
Narrative perspective / opinion article. Not systematic review, not primary research.
Sample
Not applicable
Intervention
Not applicable
Endpoints
Not applicable

What the study found, in plain language

This is a two-page perspective article, not a research study. Christopher Shade, PhD — founder and CEO of Quicksilver Scientific, a supplement company that markets a liposomal NMN product — walks a clinician audience through why nicotinamide mononucleotide (NMN) has drawn interest as an anti-aging molecule. The framing is that NAD+, a coenzyme essential for cellular repair and energy production, declines with age, and that NMN supplementation may raise NAD+ levels and produce downstream healthspan benefits.

The article opens with the World Health Organization's 2018 addition of aging to the International Classification of Diseases and uses that framing to argue for pharmacological approaches to age-related decline. It then summarises the enzymatic pathways connecting nicotinamide (vitamin B3) to NAD+ via NMN, describes the roles of the NAMPT enzyme and the Slc12a8 transporter, and reviews reported effects of NMN in mouse studies — including improved insulin sensitivity, improved mitochondrial function, cardiovascular protection, cognitive protection, and preservation of skeletal muscle.

The closing section discusses the then-early state of human research on NMN and speculates that liposomal delivery may enhance NMN uptake — a claim aligned with the author's commercial product. The article contains no original data. It is a synthesis piece intended to introduce the NMN literature to clinicians rather than to add to it.

Key findings

The article reports the following claims, drawn from the primary literature it cites:

  • NAD+ decline with age. By middle age, human NAD+ levels are approximately half of youth values (per Zhu et al. 2015, cited).
  • Oral bioavailability in mice. Plasma NMN in mice rises sharply within 2.5 minutes of oral gavage, with further increases at 5–10 minutes, then declines to baseline — suggesting rapid gut absorption (per Caton et al. 2011 and Mills et al. 2016, cited).
  • Stability in water. NMN dissolved in drinking water at room temperature remained 93–99% intact for 7–10 days (per Mills et al. 2016, cited).
  • Preclinical safety signal. One-year oral NMN at doses up to 300 mg/kg was reported safe and well tolerated in normal mice (per Mills et al. 2016, cited).
  • Reported preclinical effects (mouse models). Suppression of age-related weight gain; improved insulin secretion and insulin action; improved mitochondrial function; protection from cardiac ischemia/reperfusion injury; partial restoration of aged skeletal muscle; slowed cognitive decline in Alzheimer's disease models; protection of blood-brain barrier integrity.
  • Transport mechanism. Slc12a8 was identified as a direct NMN transporter (per Grozio et al. 2019, cited); Slc12a8 expression is approximately 100-fold higher in mouse small intestine than in brain or adipose tissue.
  • Human data status at time of writing. The article notes that human trials were underway but presents no published human RCT results. References to human effects are anecdotal, citing David Sinclair's self-reported blood markers via Harvard Magazine and Kaiser Health News.

What this study can and cannot tell us

Readers should weigh this paper carefully against the following:

  1. Format. This is a narrative perspective article, not primary research, a systematic review, or a meta-analysis. It presents no original data and applies no formal review methodology.
  2. Commercial affiliation. The author is founder and CEO of Quicksilver Scientific, which manufactures and sells a liposomal NMN supplement. The article's closing section specifically advocates for liposomal delivery of NMN, aligning with the author's commercial product. No competing interests statement is printed on the article itself.
  3. Author's domain of expertise. Christopher Shade's PhD is in environmental chemistry (mercury speciation), from the University of Illinois Urbana-Champaign. His prior published work centres on heavy-metal detoxification and liposomal delivery systems — not NAD+ biology, clinical medicine, or geroscience.
  4. Evidence base is predominantly murine. Substantive efficacy claims — on insulin sensitivity, cardiac protection, muscle restoration, cognitive protection, and lifespan — are drawn from mouse studies. Human evidence referenced consists of unpublished ongoing trials and anecdotal self-report, not published human RCT data.
  5. Extrapolation risk. At the time of publication (February 2020), preclinical rodent findings on healthspan and disease endpoints had not been demonstrated in adequately powered human RCTs. Human trials published subsequently provide stronger evidence for specific endpoints; readers should consult those directly rather than relying on this perspective piece for clinical inferences.
  6. Journal weight. Integrative Medicine (Encinitas) is PubMed-indexed but is not a high-impact peer-reviewed journal. The primary studies this article cites — from Cell Metabolism, Nature Metabolism, and similar venues — carry substantially more evidentiary weight than this synthesis of them.
  7. No DOI issued. This paper has no DOI, which limits machine-readable citation tracking. The PMID (32549859) is the canonical identifier.